Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (126) 126
female (100) 100
oncology (97) 97
male (90) 90
middle aged (87) 87
index medicus (82) 82
aged (80) 80
adult (60) 60
physics (56) 56
lung cancer (55) 55
lung neoplasms - drug therapy (49) 49
chemotherapy (48) 48
cancer (41) 41
lung neoplasms - pathology (41) 41
aged, 80 and over (36) 36
carcinoma, non-small-cell lung - drug therapy (35) 35
mutation (33) 33
respiratory system (32) 32
electricity (31) 31
gefitinib (31) 31
measuring (29) 29
testing (29) 29
performing operations (28) 28
transporting (28) 28
chemistry (26) 26
lung cancer, non-small cell (26) 26
treatment outcome (26) 26
metallurgy (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (23) 23
carcinoma, non-small-cell lung - pathology (23) 23
care and treatment (23) 23
neoplasm staging (23) 23
patients (23) 23
general tagging of cross-sectional technologies spanning over several sections of the ipc (22) 22
general tagging of new technological developments (22) 22
non-small cell lung cancer (22) 22
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (22) 22
therapy (22) 22
lung neoplasms - mortality (21) 21
analysis (20) 20
animals (20) 20
human necessities (20) 20
metastasis (20) 20
lung neoplasms - genetics (19) 19
research (19) 19
carcinoma, non-small-cell lung - mortality (18) 18
cancer therapies (17) 17
disease-free survival (17) 17
japan (17) 17
medicine & public health (17) 17
trial (17) 17
investigating or analysing materials by determining theirchemical or physical properties (16) 16
antineoplastic agents - therapeutic use (15) 15
carboplatin (15) 15
protein kinase inhibitors - therapeutic use (15) 15
rats (15) 15
survival (15) 15
tumors (15) 15
tyrosine (15) 15
acquired-resistance (14) 14
basic electric elements (14) 14
docetaxel (14) 14
electric communication technique (14) 14
heating (14) 14
prognosis (14) 14
retrospective studies (14) 14
technologies or applications for mitigation or adaptation againstclimate change (14) 14
blasting (13) 13
calculating (13) 13
computing (13) 13
counting (13) 13
erlotinib (13) 13
genetic aspects (13) 13
hematology, oncology and palliative medicine (13) 13
lighting (13) 13
lung neoplasms - diagnosis (13) 13
mechanical engineering (13) 13
non-small cell lung carcinoma (13) 13
optics (13) 13
pulmonary/respiratory (13) 13
survival rate (13) 13
testing static or dynamic balance of machines orstructures (13) 13
testing structures or apparatus not otherwise provided for (13) 13
tumor cells, cultured (13) 13
weapons (13) 13
adenocarcinoma - pathology (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
combustion engines (12) 12
hot-gas or combustion-product engine plants (12) 12
nivolumab (12) 12
oncology, experimental (12) 12
open-label (12) 12
pictorial communication, e.g. television (12) 12
protein-tyrosine kinase (12) 12
receptor, epidermal growth factor - genetics (12) 12
climate change mitigation technologies related totransportation (11) 11
diagnosis (11) 11
epidermal growth factor receptors (11) 11
hygiene (11) 11
medical or veterinary science (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
by Hida, Toyoaki, MD and Nokihara, Hiroshi, MD and Kondo, Masashi, MD and Kim, Young Hak, MD and Azuma, Koichi, MD and Seto, Takashi, MD and Takiguchi, Yuichi, Prof and Nishio, Makoto, MD and Yoshioka, Hiroshige, MD and Imamura, Fumio, MD and Hotta, Katsuyuki, Prof and Watanabe, Satoshi, MD and Goto, Koichi, MD and Satouchi, Miyako, MD and Kozuki, Toshiyuki, MD and Shukuya, Takehito, MD and Nakagawa, Kazuhiko, Prof and Mitsudomi, Tetsuya, Prof and Yamamoto, Nobuyuki, Prof and Asakawa, Takashi, PhD and Asabe, Ryoichi, MS and Tanaka, Tomohiro, MS and Tamura, Tomohide, Dr
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Quantitative detection of ALK fusion breakpoints in plasma cell-free DNA from patients with non-small cell lung cancer using PCR-based target sequencing with a tiling primer set and two-step mapping/alignment
by Kunimasa, Kei and Kato, Kikuya and Imamura, Fumio and Kukita, Yoji
PloS one, ISSN 1932-6203, 2019, Volume 14, Issue 9, p. e0222233
Tyrosine kinase inhibitors targeted to anaplastic lymphoma kinase (ALK) have been demonstrated to be effective for lung cancer patients with an ALK fusion... 
Polymerase chain reaction | Care and treatment | Usage | Lung cancer | Patient outcomes | Analysis | Genetic aspects | Nucleotide sequencing | Health aspects | Methods | Gene fusion | DNA sequencing | Laboratories | Pipelines | Genomics | ALK protein | Oncology | Mapping | Genomes | Hybridization | Quantitation | Cell fusion | Kinases | Data bases | Gene sequencing | Alignment | Primers | Tiling | Fusion protein | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Tyrosine | Breakpoints | Data analysis | Adapters | Non-small cell lung carcinoma | Lymphoma | Gene amplification | Biopsy | Ligands | Lymphomas | Mutation | Deoxyribonucleic acid | DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
by Soria, Jean-Charles and Ohe, Yuichiro and Vansteenkiste, Johan and Reungwetwattana, Thanyanan and Chewaskulyong, Busyamas and Lee, Siow-Ming and Lee, Ki Hyeong and Dechaphunkul, Arunee and Imamura, Fumio and Nogami, Naoyuki and Kurata, Takayasu and Okamoto, Isamu and Zhou, Caicun and Cho, Byoung Chul and Cho, Eun Kyung and Cheng, Ying and Voon, Pei Jye and Planchard, David and Su, Wu-Chou and Gray, Jhanelle E and Hodge, Rachel and Marotti, Marcelo and Rukazenkov, Yuri and Ramalingam, Suresh S and FLAURA Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
by Goto, Koichi, Dr and Ohe, Yuichiro, MD and Shibata, Taro, MSc and Seto, Takashi, MD and Takahashi, Toshiaki, MD and Nakagawa, Kazuhiko, Prof and Tanaka, Hiroshi, MD and Takeda, Koji, MD and Nishio, Makoto, MD and Mori, Kiyoshi, MD and Satouchi, Miyako, MD and Hida, Toyoaki, MD and Yoshimura, Naruo, MD and Kozuki, Toshiyuki, MD and Imamura, Fumio, MD and Kiura, Katsuyuki, Prof and Okamoto, Hiroaki, MD and Sawa, Toshiyuki, MD and Tamura, Tomohide, MD and JCOG0605 Investigators and JCOG0605 investigators
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Summary Background Etoposide and irinotecan are key drugs in the treatment of small-cell lung cancer. We did this study to investigate whether combined... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY-GROUP | ETOPOSIDE/CISPLATIN | THERAPY | PROGNOSTIC-FACTORS | ONCOLOGY | CLINICAL-TRIALS | DISEASE | INTENSIVE WEEKLY CHEMOTHERAPY | COMBINATION | III TRIAL | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Survival Rate | Small Cell Lung Carcinoma - drug therapy | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Small Cell Lung Carcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Adult | Camptothecin - administration & dosage | Female | Aged | Neoplasm Staging | Camptothecin - analogs & derivatives | Medical colleges | Care and treatment | Relapse | Chemotherapy | Lung cancer | Etoposide | Respiratory agents | Product development | College teachers | Diseases | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: A case control study
by Maeda, Jun and Higashiyama, Masahiko and Imaizumi, Akira and Nakayama, Tomio and Yamamoto, Hiroshi and Daimon, Takashi and Yamakado, Minoru and Imamura, Fumio and Kodama, Ken
BMC Cancer, ISSN 1471-2407, 12/2010, Volume 10, Issue 1, pp. 690 - 690
Background: The amino-acid balance in cancer patients often differs from that in healthy individuals, because of metabolic changes. This study investigated the... 
DIAGNOSIS | REAGENTS | MICROENVIRONMENT | ONCOLOGY | DISCRIMINATION | EXPRESSION | BREAST | Metabolomics | Predictive Value of Tests | Amino Acids - blood | Prognosis | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - diagnosis | Chromatography, High Pressure Liquid | Mass Screening - methods | Case-Control Studies | Young Adult | Spectrometry, Mass, Electrospray Ionization | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Reproducibility of Results | Japan | Logistic Models | Biomarkers, Tumor - blood | Carcinoma, Non-Small-Cell Lung - blood | ROC Curve | Aged | Lung Neoplasms - blood | Lung Neoplasms - diagnosis | Analysis | Amino acids | Diagnosis | Research | Lung cancer, Non-small cell | Methods | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment
by Uchida, Junji and Imamura, Fumio and Kukita, Yoji and Oba, Shigeyuki and Kumagai, Toru and Nishino, Kazumi and Inoue, Takako and Kimura, Madoka and Kato, Kikuya
Cancer Science, ISSN 1347-9032, 03/2016, Volume 107, Issue 3, pp. 353 - 358
Circulating tumor DNA (ctDNA) is an emerging field of cancer research. For lung cancer, non‐invasive genotyping of EGFR is the foremost application. The... 
lung cancer | Carcinoembryonic antigen | epidermal growth factor receptor tyrosine kinase inhibitor | massively parallel DNA sequencer | circulating tumor DNA | Epidermal growth factor receptor tyrosine kinase inhibitor | Massively parallel DNA sequencer | Lung cancer | Circulating tumor DNA | GEFITINIB | PLASMA DNA | ACQUIRED-RESISTANCE | EGFR MUTATIONS | EMERGENCE | CELL LUNG-CANCER | HETEROGENEITY | THERAPY | ONCOLOGY | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Mutation, Missense | Biomarkers, Tumor - blood | DNA, Neoplasm - blood | DNA Mutational Analysis | Protein Kinase Inhibitors - therapeutic use | Aged, 80 and over | Female | Aged | Antineoplastic Agents - pharmacology | Biomarkers, Tumor - genetics | Lung Neoplasms - blood | Protein Kinase Inhibitors - pharmacology | DNA, Neoplasm - genetics | Tyrosine | Development and progression | Epidermal growth factor | Multiprocessing | Analysis | DNA | Phenols | Genetic research | Genetic aspects | Nucleotide sequencing | CEA (Oncology) | Cancer | DNA sequencing | Plasma | Disease | Laboratories | Cytotoxicity | Gene deletion | Kinases | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Subpopulations | Nucleotide sequence | Epidermal growth factor receptors | Invasiveness | Patients | Studies | Genotyping | Biopsy | Mutation | Genetic testing | Cytotoxic agents | Tumors | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA
by Uchida, Junji and Kato, Kikuya and Kukita, Yoji and Kumagai, Toru and Nishino, Kazumi and Daga, Haruko and Nagatomo, Izumi and Inoue, Takako and Kimura, Madoka and Oba, Shigeyuki and Ito, Yuri and Takeda, Koji and Imamura, Fumio
Clinical Chemistry, ISSN 0009-9147, 09/2015, Volume 61, Issue 9, pp. 1191 - 1196
BACKGROUND: Genotyping of EGFR (epidermal growth factor receptor) mutations is indispensable for making therapeutic decisions regarding whether to use EGFR... 
TYROSINE KINASE INHIBITORS | HETEROGENEITY | GEFITINIB | GROWTH-FACTOR-RECEPTOR | CIRCULATING TUMOR DNA | GENE | ADENOCARCINOMAS | ACQUIRED-RESISTANCE | MUTATIONS | MEDICAL LABORATORY TECHNOLOGY | PCR | Lung Neoplasms - genetics | Lung - pathology | Prospective Studies | Humans | Middle Aged | ErbB Receptors - genetics | Genotype | Male | Genotyping Techniques | DNA - blood | DNA - genetics | DNA Mutational Analysis | Sensitivity and Specificity | Aged, 80 and over | Female | Aged | High-Throughput Nucleotide Sequencing | Lung Neoplasms - blood | Mutation | Lung Neoplasms - diagnosis | Plasma | Laboratories | Lung cancer | Methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Plasma free amino acid profiling of five types of cancer patients and its application for early detection
by Miyagi, Yohei and Higashiyama, Masahiko and Gochi, Akira and Akaike, Makoto and Ishikawa, Takashi and Miura, Takeshi and Saruki, Nobuhiro and Bando, Etsuro and Kimura, Hideki and Imamura, Fumio and Moriyama, Masatoshi and Ikeda, Ichiro and Chiba, Akihiko and Oshita, Fumihiro and Imaizumi, Akira and Yamamoto, Hiroshi and Miyano, Hiroshi and Horimoto, Katsuhisa and Tochikubo, Osamu and Mitsushima, Toru and Yamakado, Minoru and Okamoto, Naoyuki
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 9, p. e24143
Background: Recently, rapid advances have been made in metabolomics-based, easy-to-use early cancer detection methods using blood samples. Among metabolites,... 
LUNG-CANCER | DIAGNOSIS | REAGENTS | MULTIDISCIPLINARY SCIENCES | URINE | OVARIAN | PERIPHERAL-BLOOD | INDEX | HMGB1 | METABOLITE | BREAST | Neoplasms - blood | Analysis of Variance | Humans | Middle Aged | Fatty Acids, Nonesterified - blood | Female | Male | Aged | Usage | Care and treatment | Oncology, Experimental | Amino acids | Development and progression | Research | Cancer patients | Metabolites | Ionization | Diagnosis | Mass spectrometry | Health aspects | Prostate cancer | High performance liquid chromatography | Cancer | Plasma | Metabolomics | Anorexia | Thoracic surgery | Profiling | Pathogenesis | Hemodialysis | Lung cancer | Colorectal cancer | Oncology | Thyroid gland | Multivariate analysis | Medical diagnosis | Cancer therapies | Stomach cancer | Blood | Urology | Proteins | Surgery | Malnutrition | Approximation | Mass spectroscopy | Breast cancer | Liquid chromatography | Metabolism | High-performance liquid chromatography | Patients | Disease control | Screening | Chemotherapy | Hospitals | Sampling methods | Kidney diseases | Prostate | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study
by Morimoto, Akira and Shioda, Yoko and Imamura, Toshihiko and Kudo, Kazuko and Kawaguchi, Hiroshi and Sakashita, Kazuo and Yasui, Masahiro and Koga, Yuhki and Kobayashi, Ryoji and Ishii, Eiichi and Fujimoto, Junichiro and Horibe, Keizo and Bessho, Fumio and Tsunematsu, Yukiko and Imashuku, Shinsaku
International Journal of Hematology, ISSN 0925-5710, 7/2016, Volume 104, Issue 1, pp. 99 - 109
The JLSG-96 study reported very low mortality rates for children newly diagnosed with multifocal Langerhans cell histiocytosis (LCH). The JLSG-02 study was... 
Clinical trials | Oncology | Chemotherapy | Medicine & Public Health | Hematology | Langerhans cell histiocytosis | MAP2K1 | MUTATIONS | HEMATOLOGY | Histiocytosis, Langerhans-Cell - mortality | Prednisolone - administration & dosage | Humans | Child, Preschool | Clinical Protocols - standards | Treatment Outcome | Cytarabine - administration & dosage | Multiple Organ Failure | Disease-Free Survival | Drug Therapy, Combination - methods | Time Factors | Adolescent | Cyclosporine - administration & dosage | Vincristine - administration & dosage | Remission Induction - methods | Child | Histiocytosis, Langerhans-Cell - drug therapy | Care and treatment | Corticosteroids | Histiocytosis | Patient outcomes | Prednisolone | Steroids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non-Small Cell Lung Cancer
by Kodama, Ken, MD and Higashiyama, Masahiko, MD and Okami, Jiro, MD and Tokunaga, Toshiteru, MD and Imamura, Fumio, MD and Nakayama, Tomio, MD and Inoue, Atsuo, MD and Kuriyama, Keiko, MD
Annals of Thoracic Surgery, ISSN 0003-4975, 2016, Volume 101, Issue 2, pp. 504 - 511
Background We retrospectively compared the oncologic outcome after segmentectomy versus lobectomy in patients with clinical (c-) T1a N0 M0 non-small cell lung... 
Surgery | Cardiothoracic Surgery | SURVIVAL | SURGERY | CARDIAC & CARDIOVASCULAR SYSTEMS | LIMITED RESECTION | RESPIRATORY SYSTEM | ANATOMIC SEGMENTECTOMY | RECURRENCE | SUBLOBAR RESECTION | MATCHED ANALYSIS | Japan - epidemiology | Carcinoma, Non-Small-Cell Lung - surgery | Prospective Studies | Survival Rate - trends | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Tomography, X-Ray Computed | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - diagnosis | Carcinoma, Non-Small-Cell Lung - mortality | Propensity Score | Pneumonectomy - methods | Time Factors | Female | Lung Neoplasms - surgery | Aged | Lung Neoplasms - diagnosis | Neoplasm Staging | Lung cancer, Non-small cell | Lung cancer, Small cell
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
by Riichiroh Maruyama and Yutaka Nishiwaki and Tomohide Tamura and Nobuyuki Yamamoto and Masahiro Tsuboi and Kazuhiko Nakagawa and Tetsu Shinkai and Shunichi Negoro and Fumio Imamura and Kenji Eguchi and Koji Takeda and Akira Inoue and Keisuke Tomii and Masao Harada and Noriyuki Masuda and Haiyi Jiang and Yohji Itoh and Yukito Ichinose and Nagahiro Saijo and Masahiro Fukuoka
Journal of Clinical Oncology, ISSN 0732-183X, 09/2008, Volume 26, Issue 26, pp. 4244 - 4252
Purpose This phase III study (V-15-32) compared gefitinib (250 mg/d) with docetaxel (60 mg/m(2)) in patients (N = 489) with advanced/metastatic non-small-cell... 
IRESSA | SURVIVAL | SUPPORTIVE CARE | VINORELBINE | EFFICACY | ONCOLOGY | PLATINUM-BASED CHEMOTHERAPY | RANDOMIZED-TRIAL | OPEN-LABEL | 60 MG/M | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Proportional Hazards Models | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Taxoids - therapeutic use | Quinazolines - therapeutic use | Survival Analysis | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study
by Kubota, Kaoru, Prof and Hida, Toyoaki, MD and Ishikura, Satoshi, MD and Mizusawa, Junki, MSc and Nishio, Makoto, MD and Kawahara, Masaaki, MD and Yokoyama, Akira, MD and Imamura, Fumio, MD and Takeda, Koji, MD and Negoro, Shunichi, MD and Harada, Masao, MD and Okamoto, Hiroaki, MD and Yamamoto, Nobuyuki, MD and Shinkai, Tetsu, MD and Sakai, Hiroshi, MD and Matsui, Kaoru, MD and Nakagawa, Kazuhiko, Prof and Shibata, Taro, MSc and Saijo, Nagahiro, Prof and Tamura, Tomohide, MD and Japan Clinical Oncology Grp and Japan Clinical Oncology Group
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 106 - 113
Summary Background Four cycles of etoposide plus cisplatin and accelerated hyperfractionated thoracic radiotherapy (AHTRT) is the standard of care for... 
Hematology, Oncology and Palliative Medicine | UNITED-STATES | IRRADIATION | METAANALYSIS | ETOPOSIDE/CISPLATIN | ONCOLOGY | EARLY PALLIATIVE CARE | CLINICAL-TRIALS | JAPAN | DISEASE | COMBINATION | III TRIAL | Lung Neoplasms - mortality | Humans | Middle Aged | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Lung Neoplasms - therapy | Carcinoma, Small Cell - mortality | Chemoradiotherapy | Cisplatin - administration & dosage | Carcinoma, Small Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Camptothecin - administration & dosage | Dose Fractionation | Female | Aged | Carcinoma, Small Cell - pathology | Neoplasm Staging | Camptothecin - analogs & derivatives | Medical colleges | Care and treatment | Nuclear radiation | Lung cancer | Etoposide | College teachers | Radiotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights